Napsagatran hydrate (Ro 46-6240 hydrate) |
| Catalog No.GC34032 |
El hidrato de napsagatrÁn (hidrato de Ro 46-6240) es un inhibidor de trombina novedoso y especÍfico.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 159668-20-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Napsagatran hydrate is a novel and specific thrombin inhibitor.
Napsagatran (Ro 46-6240), the selective thrombin inhibitor, induces a dose-dependent prolongation of the activated partial thromboplastin time (aPTT) and prothrombin time (PT) that is evident 15 min after administration of the bolus of Napsagatran. Napsagatran also reduces the time to reperfusion in a dose-dependent manner and delays or prevents reocclusion[1]. The decreasing intracellular amount and efflux of compound from the cells into the medium is measured. The measured CLint,efflux values are 0.13±0.06, 3.2±0.6, 10.1±2.3, and 110±2.8 for Digoxin, Fexofenadine, Napsagatran, and Rosuvastatin, respectively, thus representing drugs with a >800-fold range of efflux rates[2].
After the first hour of drug administration (from 0 to 60 min), the incorporated radioactivity into thrombi increased from baseline by 73±13, 67±22 and 32±10% in placebo, AP-1 and Napsagatran-treated rabbits, respectively. Statistical analysis confirm that thrombus growth in the placebo and AP-1 treated rabbits is not different. In contrast, reduction of 125I-fibrinogen incorporation by Napsagatran is statistical different from the placebo group (P<0.01)[3].
[1]. Pratico D, et al. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence thatthrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. J Pharmacol Exp Ther. 1997 Jun;281(3):1178-85. [2]. Lundquist P, et al. Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model. Drug Metab Dispos. 2014 Mar;42(3):459-68. [3]. Himber J, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost. 2003 May;1(5):889-95.
Kinase experiment: | Hepatocytes in 12-well plates are preloaded until a maximal intracellular concentration is reached. Measuring the compound efflux at maximal intracellular concentration gives the efflux at steady state. Preload times and compound concentrations are decided from measured uptake data in pilot experiments (Digoxin, 10 μM for 15 minutes; Fexofenadine, 1 μM for 30 minutes; Napsagatran, 10 μM for 30 minutes; and Rosuvastatin, 1 μM for 15 minutes). After preloading, the wells are washed three times in 37°C Krebs-Henseleit buffer with 10 mM HEPES (GIBCO) pH 7.4 (KHL) to ensure that the wells are free from remaining compound. Efflux experiments are started by adding 300 μL KHL (37°C) to each well. Cells are also lysed immediately after washing to determine the initial intracellular concentrations at the start of the experiment. The contribution of ABC-efflux transporter activity to the measured efflux is assayed using 0.5 μM of the inhibitors Elacridar and Fumitremorgin C (FTC)[2]. |
Animal experiment: | Rabbits[3]The experiment is initiated by a bolus injection followed by infusion of 125I-human fibrinogen. Increase of tracer uptake within 30 min infusion of more than 30% of background value is indicative of onset of thrombus growth and thus, the counts are set to zero and Rabbits receive either Napsagatran a specific thrombin inhibitor (10 µg/kg per min in continuous i.v. infusion) or repetitive i.v. bolus of the monoclonal antiRabbits TF antibody AP-1 (600 µg/kg) at hourly intervals. The placebo-treated Rabbits (control group) receive either saline infused at 1 mL/kg or four boli of an irrelevant IgG Rabbits mAb. |
References: [1]. Pratico D, et al. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence thatthrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. J Pharmacol Exp Ther. 1997 Jun;281(3):1178-85. | |
| Cas No. | 159668-20-9 | SDF | |
| Canonical SMILES | O=C(NC[C@H]1CN(C(N)=N)CCC1)C[C@@H](C(N(C2CC2)CC(O)=O)=O)NS(C3=CC4=CC=CC=C4C=C3)(=O)=O.O | ||
| Formula | C26H36N6O7S | M.Wt | 576.67 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7341 mL | 8.6705 mL | 17.3409 mL |
| 5 mM | 346.8 μL | 1.7341 mL | 3.4682 mL |
| 10 mM | 173.4 μL | 867 μL | 1.7341 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *